Trials / Unknown
UnknownNCT03115762
Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects
Pharmacokinetics,Safety and Immunogenicity of ASKB1202 in Chinese Healthy Subjects: a Randomized, Double-blinded, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 126 (estimated)
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This trial will investigate the pharmacokinetic,immunogenicity and safety biosimilarity of ASKB1202 compared to bevacizumab sold in China and Europe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | bevacizumab | recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells |
| BIOLOGICAL | ASKB1202 |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2017-04-14
- Last updated
- 2017-04-14
Source: ClinicalTrials.gov record NCT03115762. Inclusion in this directory is not an endorsement.